These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37849520)

  • 1. Health Care Provider Prescribing Habits and Barriers to Use of New Type 2 Diabetes Medications: A Single-System Survey Study.
    Yaseen A; Lahiri SW
    Clin Diabetes; 2023; 41(4):490-501. PubMed ID: 37849520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits.
    Gao Y; Peterson E; Pagidipati N
    Am Heart J; 2020 Jun; 224():47-53. PubMed ID: 32304879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved populations.
    Ogunsanmi DO; Harrison AT; Pakker AR; Kovesdy CP; Bailey JE; Surbhi S
    J Manag Care Spec Pharm; 2023 Jun; 29(6):699-711. PubMed ID: 37276038
    [No Abstract]   [Full Text] [Related]  

  • 4. Factors Affecting Prescribing of Type 2 Diabetes Medications in Older Adults within an Integrated Healthcare System.
    Lussier ME; Gionfriddo MR; Graham JH; Wright EA
    J Gen Intern Med; 2024 Feb; 39(2):195-200. PubMed ID: 37783983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 2 Diabetes Prescribing Habits amongst Providers to an Underserved Population.
    King CA; Fontem AA; King BS; Gothard D
    Innov Pharm; 2019; 10(4):. PubMed ID: 34007585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study.
    Korayem GB; Alshaya OA; Alghamdi AA; Alanazi SS; Almutib RT; Alsaileek M; Alrashidi A; Aldosari N; Bin Sheraim N; Al Yami MS; Almohammed OA
    Front Public Health; 2022; 10():1031306. PubMed ID: 36408008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors Influencing the Choice of Glucose-Lowering Medications Among Physicians Treating Patients With Type 2 Diabetes.
    AlSofiani ME; AlHalees DZ; Aljebreen JA; Abu Dahesh JA; Bamogaddam GS; AlBraithen GM; Jammah A
    Cureus; 2024 Feb; 16(2):e53844. PubMed ID: 38465107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-series analysis of recent antihyperglycemic medication prescribing trends for a diverse sample of Medicare enrollees with type 2 diabetes mellitus in an integrated health system.
    Miller MJ; DiNucci AJ; Jalalzai R; Rabinovich N; Roblin DW
    Am J Health Syst Pharm; 2022 Jun; 79(12):950-959. PubMed ID: 35176753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study.
    Hao R; Myroniuk T; McGuckin T; Manca D; Campbell-Scherer D; Lau D; Yeung RO
    BMC Prim Care; 2022 May; 23(1):124. PubMed ID: 35606699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low Use of Guideline-recommended Cardiorenal Protective Antihyperglycemic Agents in Primary Care: A Cross-sectional Study of Adults With Type 2 Diabetes.
    Marasinghe DH; Butalia S; Garies S; Drummond N; Kim JW; Senior PA
    Can J Diabetes; 2022 Jul; 46(5):487-494. PubMed ID: 35739042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of opioid safety initiatives, prescribing patterns for opioid and naloxone, and perceived barriers to prescribing naloxone: Cross-sectional survey results based on practice type, scope, and location.
    Kohan LR; Elmofty D; Pena I; Liao C
    J Opioid Manag; 2021; 17(1):19-38. PubMed ID: 33735425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP-1, GIP receptor agonists, and dual agonists.
    Garvey WT; Mahle CD; Bell T; Kushner RF
    Obes Sci Pract; 2024 Jun; 10(3):e756. PubMed ID: 38708040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
    Kintzoglanakis K; Diamantis C; Mariolis A; Paschou SA
    Diab Vasc Dis Res; 2024; 21(4):14791641241269743. PubMed ID: 39139128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System.
    Luo J; Feldman R; Rothenberger S; Korytkowski M; Fischer MA; Gellad WF
    J Gen Intern Med; 2022 Nov; 37(14):3562-3569. PubMed ID: 35048301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect.
    Gómez-Huelgas R; Sanz-Cánovas J; Cobos-Palacios L; López-Sampalo A; Pérez-Belmonte LM
    Eur J Intern Med; 2022 Feb; 96():26-33. PubMed ID: 34799233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review.
    Hong D; Si L; Jiang M; Shao H; Ming WK; Zhao Y; Li Y; Shi L
    Pharmacoeconomics; 2019 Jun; 37(6):777-818. PubMed ID: 30854589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in diabetes medication prescribing from 2018 to 2021: A cross-sectional analysis.
    Riad J; Abdelmalek F; Ivers N; Tadrous M
    PLoS One; 2024; 19(8):e0307451. PubMed ID: 39146274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicare formulary restrictions for glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors used in type 2 diabetes mellitus: 2019-2023.
    Wisniewski B; Smith E; Kaur J; Sherling C; Vanapalli S; Lussier M
    J Manag Care Spec Pharm; 2024 Jan; 30(1):34-42. PubMed ID: 38153863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A survey of barriers and facilitators to the adoption of buprenorphine prescribing after implementation of a New Jersey-wide incentivized DATA-2000 waiver training program.
    Nyaku AN; Zerbo EA; Chen C; Milano N; Johnston B; Chadwick R; Marcello S; Baston K; Haroz R; Crystal S
    BMC Health Serv Res; 2024 Feb; 24(1):179. PubMed ID: 38331802
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.